MI today is a great accomplishment as it brings together for the first time all the expertise in immunology but it is above a new strategic step for all Marseille immunology players
As part of Protisvalor, the research transfer subsidiary of Aix-Marseille University, I have accompanied researchers from the University for nearly 4 years, first to identify European funding opportunities to meet their needs and then to help them develop proposals for submission to the European Commission. As an immunologist, I have participated in all stages of the innovation chain of Marseille Immunopôle, from research to industry and technology transfer. I have always followed R&D projects with particular interest on collaborative projects focused on immunology, involving both scientists, clinicians and industrials.
MI today is a great accomplishment as it brings together for the first time all the expertise in immunology but it is above a new strategic step for all Marseille immunology players. MI will make us more visible and efficient. Together, we have the unique opportunity to make Marseille metropolis a global hub for fundamental and applied immunology and a capital for immunotherapy R&D. Being involved in this very ambitious project is a privilege and a real responsibility!#ecosystème #industrie
MI-mAbs allows researchers to validate the therapeutic potential of their discovery and permits industrials to focus their efforts on the most promising drug candidate
With MI-mAbs and other cluster platforms, CIPHE is somewhat the "technology back office" of Marseille Immunopole.
Today Marseille Immunopôle is a great opportunity to challenge our discipline with novel perspectives.
AMU, IPC, CRCM
The Pioneer Project is unique as a strong public/private partnership between academia, a medical cancer center, 3 biotechs and a major pharma
Bernard A. FOX
Providence Cancer Institute, Portland, Oregon | UbiVac